FDA
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
-
-
-
-
-
-
-
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
-
-
-
-
-
-
-
Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001
-
-
-
-
-
-
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
-
-
-
-
-
-
-
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
-
-
-
-
-
-
-
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

